Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL Equity-to-Asset is 0.78 as of Dec. 2025, which is 10% below its 10-year median of 0.87. The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Control Bionics ranks better than 72.72% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Control Bionics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$7.73 Mil. Control Bionics's Total Assets for the quarter that ended in Dec. 2025 was A$9.93 Mil.
Therefore, Control Bionics's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.78.
The historical rank and industry rank for Control Bionics's Equity-to-Asset or its related term are showing as below:
ASX:CBL'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67 Med: 0.87 Max: 0.98
Current: 0.78
During the past 6 years, the highest Equity to Asset Ratio of Control Bionics was 0.98. The lowest was 0.67. And the median was 0.87.
ASX:CBL's Equity-to-Asset is ranked better than 72.72% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ASX:CBL: 0.78
Control Bionics (ASX:CBL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Control Bionics Equity-to-Asset Related Terms
Control Bionics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Control Bionics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Control Bionics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Control Bionics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Control Bionics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Equity-to-Asset of 0.78 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Control Bionics and its competitors. This is 10% below median its historical median of 0.87. Over the past decade, Control Bionics' Equity-to-Asset has ranged from 0.67 to 0.98. According to the industry distribution chart, Control Bionics ranks #233 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 27.3%.
Is Control Bionics' Equity-to-Asset too high?
Control Bionics' current Equity-to-Asset of 0.78 is 10% below median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 0.98. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Control Bionics' value of 0.78 is 21.9% above this industry median. Based on the distribution chart, Control Bionics ranks #233 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Control Bionics' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #233 out of 854 companies for Equity-to-Asset. This puts Control Bionics in the upper half of its industry. The industry median Equity-to-Asset is 0.64. Control Bionics' value of 0.78 is 21.9% above this benchmark. Historically, Control Bionics' own Equity-to-Asset has ranged from 0.67 to 0.98 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 0.64, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current Equity-to-Asset of 0.78 is 21.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Equity-to-Asset is 0.78, which is 10% below median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.06 — trading 106.7% above its estimated fair value. The current Equity-to-Asset is 0.78, which is 10% below median its 10-year median of 0.87 and 21.9% above the Medical Devices & Instruments industry median of 0.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Equity-to-Asset is 0.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
